Biotechnology
Ortho Clinical Diagnostics Names Joseph M. Busky Chief Financial Officer
RARITAN, New Jersey, July 7, 2020 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics backed by The Carlyle Group, announced Joseph M. Busky has joined the Company as Chief Financial Officer, effective July 7, 2020. Busky, who previously served as Chief Financial O...
2020-07-07 05:18
1730
New strategic partnership to develop next-generation T cell detection reagents
SHANGHAI, China and COPENHAGEN, Denmark, July 2, 2020 /PRNewswire/ -- Today two MedTech companies, Polaris Biology ofChina and Tetramer Shop of Denmark, announce a strategic partnership to co-develop and distribute technologies that accelerate T cell science. First on the agenda is to commerciali...
2020-07-02 21:00
1312
Affinity discovers potent SARS-CoV-2 antibodies
MELBOURNE, Australia, July 2, 2020 /PRNewswire/ -- Melbourne-based Affinity Biosciences Pty Ltd (Affinity), a privately held company focused on antibody discovery for cancer therapeutics, today announces the discovery of potent antibodies with therapeutic potential against COVID-19. In March, Af...
2020-07-02 12:25
4750
Transcenta Announces First Patient Dosed in Phase I Clinical Trial of Claudin18.2 Targeting Monoclonal Antibody TST001 in the US
SUZHOU, China, July 1, 2020 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced today that the first subject has been dosed successfull...
2020-07-01 23:00
1081
Hitachi and ThinkCyte announce collaboration to develop an AI-driven cell analysis and sorting system
TOKYO, July 1, 2020 /PRNewswire/ -- Hitachi, Ltd. (TSE: 6501, "Hitachi") and ThinkCyte, Inc. ("ThinkCyte") today announced that they have entered into a collaboration focused on developing an artificial intelligence (AI)-driven cell analysis and sorting system. Hitachi provides a broad range of s...
2020-07-01 22:00
6443
Thermo Fisher Scientific Launches New MAS Omni Infectious Disease Quality Controls
FREMONT, California, July 1, 2020 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific MAS Omni Infectious Disease quality control sets for monitoring serological assays for analytes such as HIV 1&2, Hepatitis B &...
2020-07-01 20:00
1803
Anti-viral and Anti-Inflammatory Response: GoldenBiotech's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA
TAIPEI, July 1, 2020 /PRNewswire/ -- Golden Biotechnology Corp. (GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug (IND) application for a Phase II clinical trial of Antroquinonol (Hocena®) on COVID-19 patients in...
2020-07-01 18:36
2940
Mentice Appoints Thanos Karras as Americas General Manager to Accelerate Group's Growth Strategy
GOTHENBURG, Sweden, July 1, 2020 /PRNewswire/ -- Mentice AB (STO: MNTC) today announced the appointment ofThanos Karras as the company's new General Manager for Americas. Thanos' appointment will play a critical role in supporting Mentice's continual growth strategy and will help accelerate its l...
2020-07-01 16:52
1464
RhoVac Marketed in International Press
STOCKHOLM, July 1, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") is marketed in the latest edition of the international trade press outlet, MedNous, through a written commentary by CEOAnders Månsson. In order to further attract the attention of potential partners and increase their interest in Rh...
2020-07-01 15:49
1489
Immvira Announces the Appointment of Carl Yeung as Chief Financial Officer
SHENZHEN, China, June 30, 2020 /PRNewswire/ -- Today Immvira Group Company (Immvira or the "Company"), a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, announces the appointment ofCarl Yeung as Chief Financial Officer, report...
2020-07-01 08:30
2085
FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
DARMSTADT, Germany and NEW YORK, July 1, 2020 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with...
2020-07-01 07:30
7760
Janssen Korea Ltd. and Johnson & Johnson Innovation Announce Launch of Seoul Innovation QuickFire Challenge for Healthcare in the New Normal in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute
- QuickFire Challenge calls on innovators to identify and accelerate potential solutions aiming to improve patient care in our post-COVID world. - Awardees will receive up to KRW150,000,000 (approximately US $125,000)[1], residence at the Seoul Bio Hub, and mentorship and coaching from experts at...
2020-07-01 05:30
2686
AGC Biologics Expands Development Capacities for pDNA Services at Heidelberg Site
Expansion will help meet the growing demand for plasmid DNA offerings SEATTLE, June 30, 2020 /PRNewswire/ -- Committed to continuous innovation and expansion of its service offerings, AGC Biologics has announced the expansion of its pDNA Center of Excellence in Heidelberg, Germany. The global bi...
2020-06-30 21:00
2345
Ajinomoto Bio-Pharma Services Introduces AJILITY Fast Track Platform for Drug Product Manufacturing
SAN DIEGO, June 30, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the launch of AJILITY™, a flexible and agile drug product manufacturing platform, designed to ...
2020-06-30 20:10
1551
'Curing Cancer without Surgery'
* "Successful disappearance of tumors in subjects upon administering the pain-free anticancer drug, Polytaxel, without side effects such as weight loss." * Suppressed 99.8% of tumors despite a non-toxic dose…more effective than existing FDA-approved pancreatic cancer drugs. * Hopes for a Kore...
2020-06-30 15:10
1508
Thrombosis Research Institute (TRI) Announce ETHIC Trial to Evaluate the Potential Benefits of Early Administration of LMWH in Patients with COVID-19
- Clinical trial will recruit approximately 1400 patients in 10 countries starting in July - Participants will be randomised to receive the low molecular weight Heparin enoxaparin or current standard of care for up to 3 weeks from the time of diagnosis - The study is supported through an inve...
2020-06-30 14:00
1807
AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults
AOBiome's 576 patient Phase 2b trial commences patient enrollment CAMBRIDGE, Massachusetts, June 30, 2020 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on inflammation, announced initiation of a Phase2b clinical trial in pruritus (i...
2020-06-30 13:00
1150
MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR™ Sirolimus Drug Eluting Balloon
NYON, Switzerland, June 30, 2020 /PRNewswire/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR™ 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease. This includes indications for both de-novo lesions as well as in-stent ...
2020-06-30 08:00
2231
Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2020
Added 18,488 New Subscribers in 4Q20 4Q20 Revenues Increased by 19.2% YoY to RMB299.9 Million ($42.4 Million) 4Q20 Operating Income Increased by 68.1% YoY to RMB149.3 Million ($21.1 Million) Non-GAAP Operating Income Up 58.7% YoY to RMB161.7 Million ($22.8 Million) Conference Call to be Held on Jun...
2020-06-30 04:16
13645
RevImmune Announces Phase II Trial of the T-Cell Growth Factor CYT107 for COVID-19
Under Way in Europe Since May, In Preparation in the U.S. Designated As An Urgent Public Health National Priority In U.K. BETHESDA, Maryland, June 29, 2020 /PRNewswire/ -- RevImmune, a privately held biotechnology company developing CYT107 immune therapy for infectious diseases and cancer, an...
2020-06-29 21:00
2454
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5203
